The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma

Published:2015-04-18 Issue:1 Volume:15 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Ho Thai H,Liu Xian-De,Huang Yanqing,Warneke Carla L,Johnson Marcella M,Hoang Anh,Tamboli Pheroze,Wang Fen,Jonasch Eric

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/s12885-015-1302-1/fulltext.html

Reference25 articles.

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

2. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin Jr WG, et al. Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference. Cancer. 2009;115(10 Suppl):2247–51.

3. Bhide RS, Lombardo LJ, Hunt JT, Cai ZW, Barrish JC, Galbraith S, et al. The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. Mol Cancer Ther. 2010;9(2):369–78.

4. Allen E, Walters IB, Hanahan D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition. Clin Cancer Res. 2011;17(16):5299–310.

5. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell. 2005;8(4):299–309.

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Blood- and Urine-Based Liquid Biopsy for Early-Stage Cancer Investigation: Taken Clear Renal Cell Carcinoma as a Model;Molecular & Cellular Proteomics;2023-08

2. Therapeutic sequencing in advanced renal cell carcinoma: How to choose considering clinical and biological factors;Critical Reviews in Oncology/Hematology;2023-01

3. Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review;Journal of Modern Oncology;2022-07-15

4. Gene Expression-Based Signature Can Predict Sorafenib Response in Kidney Cancer;Frontiers in Molecular Biosciences;2022-03-14

5. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers;Pharmacological Research;2021-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3